Paul Beresford and Lou Welebob of Agilent Technologies discuss how partnerships are vital in addressing the evolving needs of pharma for complex diagnostics and CDx development.
Discussions center around the importance of working with pharmaceutical companies to drive medical innovation and improve patient outcomes, helping to speed up the process of bringing the right treatments to the right patients at the right time.
Topics discussed include the importance of broadening technological focus on immunohistochemistry, such as bridging into digital biology and imaging as well as multiplexing. Spatial biology is touched upon, specifically looking at how spatial profiling can be used to determine cell proximity within the tumor microenvironment, potentially correlated to drug efficacy.
Looking ahead, both speakers point to the potential to use machine learning in key areas such as the development of assays for use across laboratories globally.
To discover the full range of insights from life sciences, diagnostics and applied chemical markets specialist Agilent Technologies, listen to the full podcast.
See omnystudio.com/listener for privacy information.
